Your shopping cart is empty!
Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
Catalog: | HY-13859 |
Brand: | MCE |
CAS: | 163252-36-6 |
MDL | MFCD00935785 |
---|---|
Molecular Weight | 260.22 |
Molecular Formula | C10H13FN2O5 |
SMILES | O[C@@H]1[C@@H](F)[C@@H](N2C(NC(C(C)=C2)=O)=O)O[C@H]1CO |
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase . Clevudine is active against cowpox virus respiratory infection in mice [1] [2] [3] .
Clevudine (L-FMAU) shows some activity against Epstein-Barr virus [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00313287 | Bukwang Pharmaceutical |
Hepatitis B
|
June 2003 | Phase 3 |
NCT00313261 | Bukwang Pharmaceutical |
Hepatitis B
|
June 2003 | Phase 2 |
NCT04891302 | Bukwang Pharmaceutical |
COVID-19
|
March 19, 2021 | Phase 2 |
NCT00672867 | Bukwang Pharmaceutical |
Patients With LC-B
|
December 2007 | Phase 3 |
NCT00305019 | Bukwang Pharmaceutical |
Hepatitis B
|
July 2002 | Phase 2 |
NCT00313274 | Bukwang Pharmaceutical |
Hepatitis B
|
July 2003 | Phase 3 |
NCT01266005 | Bukwang Pharmaceutical |
Chronic Hepatitis B
|
August 2009 | Phase 4 |
NCT00501124 | Bukwang Pharmaceutical |
Hepatitis B
|
May 2007 | Phase 4 |
NCT00798460 | Inje University|Bukwang Pharmaceutical |
Chronic Hepatitis B
|
December 2008 | Phase 4 |
NCT04347915 | Bukwang Pharmaceutical |
COVID-19
|
May 26, 2020 | Phase 2 |
NCT00362635 | Bukwang Pharmaceutical |
Hepatitis B
|
August 2006 | Phase 3 |
NCT01264354 | Bukwang Pharmaceutical |
Chronic Hepatitis B
|
March 2010 | Phase 4 |
NCT00823342 | French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Pharmasset |
HBe Negative Chronic Hepatitis B|Hepatitis B Viral Infection
|
December 2008 | Phase 3 |
NCT01264094 | Bukwang Pharmaceutical |
Chronic Hepatitis B
|
November 2009 | Phase 4 |
NCT00362505 | Bukwang Pharmaceutical |
Hepatitis B
|
June 2004 | Phase 3 |
NCT00558493 | Bukwang Pharmaceutical |
Chronic Hepatitis B
|
November 2007 | Phase 4 |
NCT00362700 | Bukwang Pharmaceutical |
Hepatitis B
|
July 2003 | Phase 2 |
NCT01192854 | Eisai Co., Ltd.|Eisai Inc. |
Chronic Hepatitis B
|
February 2010 | Phase 3 |
NCT00496002 | Pharmasset |
Chronic Hepatitis|Hepatitis B
|
August 2007 | Phase 3 |
NCT00044135 | Triangle Pharmaceuticals |
Hepatitis B
|
August 2002 | Phase 2 |
NCT00496158 | Pharmasset |
Chronic Hepatitis|Hepatitis B
|
August 2007 | Phase 3 |
NCT01264367 | Bukwang Pharmaceutical |
HBeAg(&addition;) Chronic Hepatitis B
|
December 2008 | Phase 4 |
NCT00641082 | Bukwang Pharmaceutical |
HBeAg(-) Chronic Hepatitis B With Compensated Liver Function
|
February 2008 | Phase 4 |
NCT00558818 | Bukwang Pharmaceutical |
Chronic Hepatitis B
|
June 2007 | Phase 4 |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : 100 mg/mL ( 384.29 mM ; Need ultrasonic)
H 2 O : ≥ 50 mg/mL ( 192.15 mM )
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 3.8429 mL | 19.2145 mL | 38.4290 mL |
5 mM | 0.7686 mL | 3.8429 mL | 7.6858 mL |
10 mM | 0.3843 mL | 1.9215 mL | 3.8429 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.